Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand domestic operations in response to possible tariffs on imported medicines. According to The Wall Street Journal, more than a dozen drugmakers have pledged over $350 billion in U.S. investments this decade to strengthen local supply chains and reduce tariff risks.
GSK (LON:GSK) revealed plans to spend $30 billion in the United States over the next five years, focusing on research, supply-chain infrastructure, and new production facilities. The investment includes $1.2 billion for a new factory near Philadelphia dedicated to developing treatments for respiratory illnesses and cancer. The move positions GSK to boost U.S. drug production while creating new jobs in the biopharma sector.
Meanwhile, Eli Lilly (NYSE:LLY) announced a $5 billion investment to build a state-of-the-art plant near Richmond, Virginia. The facility will specialize in manufacturing monoclonal antibodies and bioconjugates, critical therapies in oncology and immunology. Once operational, the plant is expected to employ approximately 650 workers, enhancing Lilly’s domestic manufacturing footprint and supporting innovation in biologic medicines.
The surge in U.S. pharmaceutical investments comes as the Trump administration considers imposing tariffs on imported drugs, with rates potentially climbing to 250% within 18 months. Such measures could significantly impact global supply chains, pushing companies to accelerate onshore production strategies.
By committing billions to U.S. manufacturing, GSK and Eli Lilly join a broader trend of pharmaceutical giants prioritizing local capacity. These investments are expected to safeguard supply resilience, stimulate job creation, and position drugmakers to better navigate policy changes affecting the global pharmaceutical market.
